dr. jahanzeb on eligibility criteria for immunotherapy trials in nsclc
Published 5 years ago • 298 plays • Length 1:56Download video MP4
Download video MP3
Similar videos
-
1:49
dr. jahanzeb on immunotherapy in elderly patients with nsclc
-
1:15
dr. jahanzeb on immunotherapy in oncogene-driven nsclc
-
1:41
dr. farago on eligibility criteria for frontline immunotherapy in sclc
-
2:21
dr. kim on clinical trial eligibility criteria in lung cancer
-
1:40
dr. piotrowska on eligibility criteria for osimertinib in lung cancer treatment
-
0:51
dr. bazhenova on ongoing clinical trials with immunotherapy in nsclc
-
32:52
immunotherapy for early-stage, resectable nsclc: from clinical trial data to guidelines
-
1:36
dr. rudin on expansion of immunotherapy in lung cancer
-
1:37
dr. borghaei on anticipated trials evaluating immunotherapy in nsclc
-
1:17
dr. chaft on investigational neoadjuvant immunotherapy approaches in nsclc
-
2:04
dr. gandhi on pembrolizumab/chemo findings in nsclc and fda approval
-
1:10
dr. subramanian on the future of immunotherapy in nsclc
-
7:11
immunotherapy in the frontline and as part of combinations for nsclc
-
1:18
dr. natale on the evolution of immunotherapy in nsclc
-
2:15
dr. wakelee on birch trial for atezolizumab in patients with nsclc
-
1:03
dr. costa on biomarkers beyond pd-l1 for immunotherapy in nsclc
-
1:33
dr. chaft on the rise of immunotherapy in lung cancer
-
1:24
dr. chaft on considerations for restarting immunotherapy in lung cancer
-
2:28
optimal duration of immunotherapy administration for patients with nsclc